Patent 8642752 was granted and assigned to Ionis Pharmaceuticals on February, 2014 by the United States Patent and Trademark Office.
Disclosed herein are antisense compounds and methods for decreasing HBV mRNA, DNA and protein expression. Such methods, compounds, and compositions are useful to treat, prevent, or ameliorate HBV-related diseases, disorders or conditions.